Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

Survodutide

Dual GLP-1/Glucagon receptor agonist29 amino acids

BHuman Studies
80
Good Credibility
1 cited study | Evidence level B

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. In Phase 3 trials, it demonstrates significant weight loss and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD).

Mechanism of Action

Dual agonist targeting GLP-1 receptors (appetite suppression, insulin secretion) and glucagon receptors (increased energy expenditure, hepatic lipid metabolism). The glucagon component drives liver fat reduction, differentiating it from GLP-1-only agonists.

Benefits

  • Up to 19% weight loss in Phase 2 trials[1]
  • Significant liver fat reduction for MASH[1]
  • Dual mechanism targets both weight and liver disease[1]
  • Once-weekly dosing[1]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

Survodutide - Dosing in Published Research

Reported routes: Subcutaneous injection
Phase 3 trials testing multiple dose levels administered SC weekly. Trials ongoing for both obesity (SYNCHRONIZE) and MASH indications.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Nausea and vomiting[1]
  • Diarrhea[1]
  • Decreased appetite[1]
  • Injection site reactions[1]
  • Long-term safety data still being collected[1]

Considering peptide research?

Survodutide is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Get the Provider Checklist

Start with the evidence and provider checklist while routing is offline.

Always consult a professional

Research & Evidence

Compare Survodutide With

References

  1. 1.Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.. JACC Heart Fail, 2024. "Survodutide produced up to 19% weight loss at 46 weeks with significant improvements in cardiometabolic markers" [PMID: 39453356]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Research Supplies

Equipment for responsible research-grade peptide handling and administration.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Survodutide FAQ